TEL HAI, Israel today announced that--
cCAM Biotherapeutics, a biopharmaceutical company focused on the discovery and development of novel immunomodulatory drugs for cancer, announced today the completion of its Series A financing . The round was led by Arkin Holdings and included participation from OrbiMed's Israel Partners, Pontifax and F.Hoffmann La Roche. ROG.VX.
cCAM Biotherapeutics is a pre-clinical stage company developing immunotherapies for cancer.
cCAM's lead agent, CM-10, is an immunomodulatory humanized monoclonal antibody that harnesses the patient's immune system to attack tumors. CM-10 targets CEACAM1, a receptor newly characterized as an immune checkpoint used by cancer cells to suppress the immune system. Upon binding to CEACAM1, CM-10 leads to a cancer specific immune response.
